Table 6.

PASI 75 and PASI 90 responses during the first and third months in patients with a BMI >30 (obese) when the biologics were evaluated separately.

Continuous variables	ADALIMUMAB (N=10)	ETANERCEPT (N=2)	INFLIXIMAB (N=4)	SERTOLIZUMAB PEGOL (N=4)	USTEKINUMAB (N=17)	SECUKINUMAB (N=19)	IXEKIZUMAB (N=5)	RISANKIZUMAB (N=2)	GUSELKUMAB (N=2)	Total biologic (N=65)
Patients who achieved PASI 75 the first month	60.0% (N=6)	0.0% (N=0)	25.0% (N=1)	50.0% (N=2)	35.3% (N=6)	42.1% (N=8)	60.0% (N=3)	0.0% (N=0)	0.0% (N=0)	40.0% (N=26)
Patients who achieved PASI 75 the third month	80.0% (N=8)	100% (N=2)	25.0% (N=1)	50.0% (N=2)	47.1% (N=8)	52.6% (N=10)	60.0% (N=3)	0.0% (N=0)	100.0% (N=2)	55.4% (N=36)
Patients who achieved PASI 90 the first month	60.0% (N=6)	0.0% (N=0)	25.0% (N=1)	25.0% (N=1)	23.5% (N=4)	42.1% (N=8)	40.0% (N=2)	0.0% (N=0)	0.0% (N=0)	33.8% (N=22)
Patients who achieved PASI 75 the third month	70.0% (N=7)	0.0% (N=0)	25.0% (N=1)	50.0% (N=2)	35.3% (N=6)	47.4% (N=9)	60.0% (N=3)	0.0% (N=0)	50.0% (N=1)	44.6% (N=29)

PASI = Psoriasis Area and Severity Index.